Anti-PD-1/PD-L1 Antibodies Combine with Chemotherapy or CTLA4 Antibodies for First-Line Treatment of Advanced Lung Cancer

被引：0
|
作者：
Fan, Y. [1 ]
Xu, X. [2 ]
机构：
[1] Zhejiang Canc Hosp, Chemotherapy, Hangzhou, Zhejiang, Peoples R China
[2] Zhejiang Prov Canc Hosp, Hangzhou, Zhejiang, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
lung cancer; Checkpoint inhibitors; chemotherapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.07-057
引用
收藏
页码：S2149 / S2150
页数：2
相关论文
共 50 条
  • [41] Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
    Boutros, Celine
    Tarhini, Ahmad
    Routier, Emilie
    Lambotte, Olivier
    Ladurie, Francois Leroy
    Carbonnel, Franck
    Izzeddine, Hassane
    Marabelle, Aurelien
    Champiat, Stephane
    Berdelou, Armandine
    Lanoy, Emilie
    Texier, Matthieu
    Libenciuc, Cristina
    Eggermont, Alexander M. M.
    Soria, Jean-Charles
    Mateus, Christine
    Robert, Caroline
    NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (08) : 473 - 486
  • [42] ANTI-PD-1 AND ANTI-PD-L1 ANTIBODIES AS IMMUNOTHERAPY AGAINST CANCER: A STRUCTURAL PERSPECTIVE
    Cordova-Bahena, Luis
    Velasco-Velazquez, Marco A.
    REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION, 2021, 73 (01): : 8 - 16
  • [43] Anti-PD-1 and Anti-PD-L1 Monoclonal Antibodies in People Living with HIV and Cancer
    Kathryn Lurain
    Ramya Ramaswami
    Robert Yarchoan
    Thomas S. Uldrick
    Current HIV/AIDS Reports, 2020, 17 : 547 - 556
  • [44] Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression
    Ken Masuda
    Hidehito Horinouchi
    Midori Tanaka
    Ryoko Higashiyama
    Yuki Shinno
    Jun Sato
    Yuji Matsumoto
    Yusuke Okuma
    Tatsuya Yoshida
    Yasushi Goto
    Noboru Yamamoto
    Yuichiro Ohe
    Journal of Cancer Research and Clinical Oncology, 2021, 147 : 245 - 251
  • [45] Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
    Celine Boutros
    Ahmad Tarhini
    Emilie Routier
    Olivier Lambotte
    Francois Leroy Ladurie
    Franck Carbonnel
    Hassane Izzeddine
    Aurelien Marabelle
    Stephane Champiat
    Armandine Berdelou
    Emilie Lanoy
    Matthieu Texier
    Cristina Libenciuc
    Alexander M. M. Eggermont
    Jean-Charles Soria
    Christine Mateus
    Caroline Robert
    Nature Reviews Clinical Oncology, 2016, 13 : 473 - 486
  • [46] Clinical benefit of anti PD-1/PD-L1 plus chemotherapy versus chemotherapy alone in first-line treatment in advanced non-small cell lung cancer: A meta-analysis
    Landre, T.
    Des Guetz, G.
    Vergnenegre, A.
    Chouaid, C.
    ANNALS OF ONCOLOGY, 2019, 30
  • [47] Identification of novel antagonistic anti-PD-1 antibodies that are non-blocking of the PD-1/PD-L1 interaction
    Fenwick, Craig
    Pellaton, Celine
    Farina, Alex
    Radja, Navina
    Pantaleo, Giuseppe
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [48] Retreatment With Anti-PD-L1 Antibody in Advanced Non-small Cell Lung Cancer Previously Treated With Anti-PD-1 Antibodies
    Fujita, Kohei
    Uchida, Naohiro
    Yamamoto, Yuki
    Kanai, Osamu
    Okamura, Misato
    Nakatani, Koichi
    Sawai, Satoru
    Mio, Tadashi
    ANTICANCER RESEARCH, 2019, 39 (07) : 3917 - 3921
  • [49] Anti-PD-1 Monoclonal Antibodies (mAbs) Are Superior to Anti-PD-L1 mAbs When Combined with Chemotherapy in First-Line Treatment for Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Network Meta-Analysis
    Wei, Joe Q. Q.
    Yuile, Alexander
    Itchins, Malinda
    Kong, Benjamin Y. Y.
    Li, Bob T. T.
    Pavlakis, Nick
    Chan, David L. L.
    Clarke, Stephen J. J.
    BIOMEDICINES, 2023, 11 (07)
  • [50] Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
    Naidoo, J.
    Page, D. B.
    Li, B. T.
    Connell, L. C.
    Schindler, K.
    Lacouture, M. E.
    Postow, M. A.
    Wolchok, J. D.
    ANNALS OF ONCOLOGY, 2015, 26 (12) : 2375 - 2391
12345